| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Faiez Zannad | Q19631268 |
| Daniela Dobre | Q82736786 | ||
| Patrick Rossignol | Q33103963 | ||
| Marco Metra | Q39274051 | ||
| P2860 | cites work | Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study | Q28167204 |
| Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors | Q28210545 | ||
| Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD) | Q28375370 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Relation of blood urea nitrogen to long-term mortality in patients with heart failure | Q30446226 | ||
| Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency | Q46940287 | ||
| The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. | Q46987014 | ||
| A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. | Q50578930 | ||
| Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? | Q50657801 | ||
| Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. | Q50908731 | ||
| Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. | Q51749328 | ||
| Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. | Q51932219 | ||
| Renal function, neurohormonal activation, and survival in patients with chronic heart failure. | Q52076638 | ||
| Implications of a health lifestyle and medication analysis for improving hypertension control. | Q52081639 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology | Q55050673 | ||
| Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction | Q58040720 | ||
| Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial) | Q68231231 | ||
| ACE-inhibitors: panacea for progressive renal disease | Q73499174 | ||
| Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function | Q74352999 | ||
| Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction | Q74587371 | ||
| Impact of myocardial function on cystatin C measurements in chronic systolic heart failure | Q81365999 | ||
| The cardiorenal syndrome: do we need a change of strategy or a change of tactics? | Q83345948 | ||
| Anaemia and renal dysfunction in chronic heart failure | Q84724840 | ||
| Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result | Q34339279 | ||
| Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure | Q34572385 | ||
| Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. | Q34575166 | ||
| Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial | Q34963382 | ||
| Serum creatinine as an index of renal function: new insights into old concepts. | Q35370592 | ||
| Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system | Q35856246 | ||
| Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age? | Q36025044 | ||
| Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate | Q36344899 | ||
| Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials | Q36488595 | ||
| The frequency of hyperkalemia and its significance in chronic kidney disease. | Q36530203 | ||
| Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. | Q36954799 | ||
| beta-Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability | Q37004479 | ||
| Anemia and mortality in heart failure patients a systematic review and meta-analysis | Q37255449 | ||
| Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide | Q37256856 | ||
| Cardiorenal syndrome | Q37324890 | ||
| Integrating albuminuria and GFR in the assessment of diabetic nephropathy | Q37531889 | ||
| The aging kidney: structural changes. | Q37792947 | ||
| Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure | Q39485940 | ||
| Neurohormonal interactions and adaptations in congestive heart failure | Q39633177 | ||
| Hyperkalemia as a complication of drug therapy | Q39771947 | ||
| Glomerular Filtration | Q39937525 | ||
| Measuring progression of diabetic nephropathy | Q40590137 | ||
| Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality | Q42946298 | ||
| Ferric carboxymaltose in patients with heart failure and iron deficiency | Q43240282 | ||
| Blood urea nitrogen and serum creatinine: not married in heart failure | Q43266279 | ||
| Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy | Q43270031 | ||
| Albuminuria in chronic heart failure: prevalence and prognostic importance | Q43291306 | ||
| Renal function as a predictor of outcome in a broad spectrum of patients with heart failure | Q43500856 | ||
| Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? | Q44790188 | ||
| Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. | Q45929238 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). | Q46480414 | ||
| Simple clinical criteria to determine the prognosis of heart failure | Q46740746 | ||
| P433 | issue | 2 | |
| P921 | main subject | heart failure | Q181754 |
| chronic heart failure | Q11829287 | ||
| P304 | page(s) | 283-290 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Heart Failure Reviews | Q2167497 |
| P1476 | title | Can we prevent or treat renal dysfunction in chronic heart failure? | |
| P478 | volume | 17 |
| Q38109588 | Clinical use of novel biomarkers in heart failure: towards personalized medicine | cites work | P2860 |
Search more.